Oliver Wyman March 14, 2024
Since the infrastructure needed to support cell and gene therapies is so complex, companies must assess supply chain issues early, even before entering human studies.
Begin with the end in mind. That’s Matthew Lakelin’s advice for companies aiming to bring cell and gene therapies to market.
Because the infrastructure needed to support cell and gene therapies is so complex, companies must consider supply chain issues very early on, even before they enter human studies, said Lakelin, Vice President of Scientific Affairs at TrakCel, a company that helps manage all components of the cell and gene therapy supply chain.
For instance, blood,...
Today's Sponsors
Today's Sponsor